Early switch to dabigatran safe for patients with intermediate-risk pulmonary embolism: PEITHO-2 trial
Germany: An early switch from heparin to dabigatran in patients with intermediate-risk pulmonary embolism is safe and effective, show results from the phase 4 PEITHO-2 trial.
The study results were published in The Lancet Haematology on August 04, 2021.
For the management of acute pulmonary embolism, the current guidelines recommend a risk-adjusted treatment strategy. However, in this specific patient category, optimal treatment (reperfusion strategies, (anticoagulant treatment, and duration of hospitalization) is currently unknown. Considering this, Frederikus A Klok, Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Netherlands, and colleagues aimed to investigate the safety and effectiveness of the treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran).
The phase 4 PEITHO-2 trial was a single-arm, multinational trial occurring at 42 hospitals across Europe. It enrolled adult 402 patients (aged ≥18 years) with symptomatic intermediate-risk pulmonary embolism, with or without deep-vein thrombosis. Patients received parenteral low-molecular-weight or unfractionated heparin for 72 h after diagnosis of pulmonary embolism before switching to oral dabigatran 150 mg twice per day following a standard clinical assessment. Median follow-up was 217 days and 370 (92%) patients adhered to the protocol.
The primary outcome was recurrent symptomatic venous thromboembolism or pulmonary embolism-related death within 6 months. The primary and safety outcomes were assessed in the intention-to-treat population. Following the advice of the data safety and monitoring board, the study was terminated early after a change in sample size based on the predefined interim analysis.
Key findings include:
- The primary outcome occurred in seven (2% patients, with all events occurring in those with intermediate-high-risk pulmonary embolism (seven [3%]).
- At 6 months, 11 (3%) of 402 patients had at least one major bleeding event and 16 (4%) had at least one clinically relevant non-major bleeding event; the only fatal hemorrhage occurred in one (<1%) patient before the switch to dabigatran.
The researchers concluded, "Our results can help to refine guideline recommendations for the initial treatment of acute intermediate-risk pulmonary embolism, optimizing the use of resources and avoiding extended hospitalization."
Reference:
The study titled, "Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial," is published in The Lancet Haematology.
DOI: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00203-9/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.